Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulgent Genetics, Inc.FLGT · Entity 2545 | President and COO | September 02, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulgent Genetics, Inc.
Report date September 02, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 359,924 |
Reported balance
After 2026-09-02 transaction · row 1
1 source rowRow 1 · 2026-09-02 · Sale · Disposed 2,127 · Balance 359,924 F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 220,816 |
Reported balance
Holding disclosure · report date 2026-09-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 220,816 F3: Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
F2: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2026 Filed Sep 3, 2026 23:47 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 2,127 | $19.66 | $41,809.16 |
DisclosureSEC source: 0001819718-26-000015 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,924 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 22:06 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,193 | $19.91 | $23,747.02 |
DisclosureSEC source: 0001819718-26-000011 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,051 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. F2 · price: The shares were sold in multiple transactions at prices ranging from $19.83 to $20.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 26, 2026 Filed Jul 28, 2026 20:32 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,361 | $19.67 | $85,780.87 |
DisclosureSEC source: 0001193125-26-321086 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,244 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 21:29 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 2,146 | $17.89 | $38,382.28 |
DisclosureSEC source: 0001819718-26-000007 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,605 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. F2 · price: The shares were sold in multiple transactions at prices ranging from $17.63 to $18.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 27, 2026 Filed May 28, 2026 21:22 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,201 | $17.60 | $21,137.60 |
DisclosureSEC source: 0001819718-26-000003 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 369,751 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. F2 · price: The shares were sold in multiple transactions at prices ranging from $17.39 to $17.76, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 26, 2026 Filed Apr 28, 2026 20:52 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,361 | $16.31 | $71,127.91 |
DisclosureSEC source: 0001193125-26-187448 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,952 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 01:01 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 8,147 | $15.33 | $124,893.51 |
DisclosureSEC source: 0001819718-26-000001 · ownership.xml · nonDerivative · entry 3 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,313 F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 01:01 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,079 | $15.33 | $16,541.07 |
DisclosureSEC source: 0001819718-26-000001 · ownership.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,460 F2 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:01 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,140 | $24.76 | $28,226.40 |
DisclosureSEC source: 0001819718-26-000001 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,539 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 31,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072640 · ownership.xml · nonDerivative · entry 8 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 385,679 F8 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2026, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 14,751 | $23.09 | $340,600.59 |
DisclosureSEC source: 0001193125-26-072640 · ownership.xml · nonDerivative · entry 7 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,717 F7 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 25, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 8,254 | $23.09 | $190,584.86 |
DisclosureSEC source: 0001193125-26-072640 · ownership.xml · nonDerivative · entry 6 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,468 F6 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 26, 2024. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 3,163 | $23.09 | $73,033.67 |
DisclosureSEC source: 0001193125-26-072640 · ownership.xml · nonDerivative · entry 5 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,722 F5 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 27,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072640 · ownership.xml · nonDerivative · entry 4 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,885 F4 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 25, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 15,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072640 · ownership.xml · nonDerivative · entry 3 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,544 F3 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 26, 2024. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 5,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072640 · ownership.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,245 F2 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023. Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 655 | $23.01 | $15,071.55 |
DisclosureSEC source: 0001193125-26-072640 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,383 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 22:02 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,711 | $27.53 | $129,693.83 |
DisclosureSEC source: 0001193125-26-027402 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,038 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,140 | $28.33 | $32,298.25 |
DisclosureSEC source: 0001193125-25-306921 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,749 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $28.27 to $28.38, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 28, 2025 Filed Dec 2, 2025 02:14 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,198 | $29.57 | $35,424.26 |
DisclosureSEC source: 0001193125-25-304294 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,889 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. F2 · price: The shares were sold in multiple transactions at prices ranging from $29.45 to $29.67, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 21:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 681 | $30.47 | $20,752.11 |
DisclosureSEC source: 0001193125-25-297323 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,087 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. F2 · price: The shares were sold in multiple transactions at prices ranging from $30.33 to $30.62, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-291451 · ownership.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,768 F3 · shares: Reflects shares transferred as a gift to the James and Karena Xie Family Foundation (the "Foundation"), of which, the reporting person is the president and has voting and investment power over all securities owned by the foundation. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 10,000 | $29.10 | $290,983.00 |
DisclosureSEC source: 0001193125-25-291451 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,768 F1 · shares: The shares were sold by the reporting person for year-end tax planning. F2 · price: The shares were sold in multiple transactions at prices ranging from $29.07 to $29.1985, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 26, 2025 Filed Oct 28, 2025 21:20 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,353 | $23.74 | $103,340.22 |
DisclosureSEC source: 0001193125-25-253871 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,768 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 21:33 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,128 | $22.03 | $24,846.12 |
DisclosureSEC source: 0001819718-25-000022 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,121 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $21.92 to $22.175, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 22:55 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,199 | $21.48 | $25,760.16 |
DisclosureSEC source: 0001819718-25-000018 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,249 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. F2 · price: The shares were sold in multiple transactions at prices ranging from $21.28 to $21.66, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 23:13 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 696 | $21.50 | $14,965.11 |
DisclosureSEC source: 0001819718-25-000008 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,448 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. F2 · price: The shares were sold in multiple transactions at prices ranging from $21.46 to $21.57, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 26, 2025 Filed Jul 29, 2025 22:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,352 | $18.37 | $79,946.24 |
DisclosureSEC source: 0000950170-25-099792 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,144 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:46 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,135 | $20.29 | $23,030.06 |
DisclosureSEC source: 0000950170-25-081045 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,496 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $20.01 to $20.70, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 27, 2025 Filed May 28, 2025 20:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,183 | $20.52 | $24,271.49 |
DisclosureSEC source: 0000950170-25-078349 · ownership.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 372,631 F3 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. F4 · price: The shares were sold in multiple transactions at prices ranging from $20.445 to $20.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 27, 2025 Filed May 28, 2025 20:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 690 | $20.58 | $14,196.96 |
DisclosureSEC source: 0000950170-25-078349 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373,814 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. F2 · price: The shares were sold in multiple transactions at prices ranging from $20.41 to $20.79, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| April 26, 2025 Filed Apr 29, 2025 20:54 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,353 | $18.88 | $82,184.64 |
DisclosureSEC source: 0000950170-25-060281 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,504 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,481 | $15.45 | $22,881.45 |
DisclosureSEC source: 0000950170-25-032782 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,857 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| February 26, 2025 Filed Mar 5, 2025 01:07 UTC Amendment | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,551 | $16.24 | $73,908.24 |
DisclosureSEC source: 0000950170-25-032777 · ownership.xml · nonDerivative · entry 3 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,338 F4 · date: The original Form 4 filed on February 27, 2025 on behalf of the reporting person inadvertently reported an incorrect transaction date. As reported in this amendment, the correct transaction date is February 26, 2025. F5 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 45,304 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029434 · ownership.xml · nonDerivative · entry 7 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 384,889 F7 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2025, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,823 | $16.29 | $29,696.67 |
DisclosureSEC source: 0000950170-25-029434 · ownership.xml · nonDerivative · entry 4 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,567 F4 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 14,297 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029434 · ownership.xml · nonDerivative · entry 3 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,390 F3 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 26, 2024. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 5,480 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029434 · ownership.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,093 F2 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 3,384 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029434 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,613 F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022. Read SEC document |
| February 25, 2025 Filed Mar 5, 2025 01:07 UTC Amendment | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 8,031 | $16.29 | $130,824.99 |
DisclosureSEC source: 0000950170-25-032777 · ownership.xml · nonDerivative · entry 2 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,585 F1 · date: The original Form 4 filed on February 27, 2025 on behalf of the reporting person inadvertently reported an incorrect transaction date. As reported in this amendment, the correct transaction date is February 25, 2025. F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of performance-based restricted stock units granted to the reporting person on February 26, 2024, which vesting was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. Read SEC document |
| February 25, 2025 Filed Mar 5, 2025 01:07 UTC Amendment | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,951 | $16.29 | $48,071.79 |
DisclosureSEC source: 0000950170-25-032777 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,616 F1 · date: The original Form 4 filed on February 27, 2025 on behalf of the reporting person inadvertently reported an incorrect transaction date. As reported in this amendment, the correct transaction date is February 25, 2025. F2 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of performance-based restricted stock units granted to the reporting person on February 23, 2023, which vesting was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 22:26 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 719 | $16.46 | $11,834.74 |
DisclosureSEC source: 0000950170-25-026887 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,229 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| January 26, 2025 Filed Jan 28, 2025 21:28 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,733 | $17.21 | $81,454.93 |
DisclosureSEC source: 0000950170-25-009840 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 329,948 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:41 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,455 | $19.50 | $28,372.35 |
DisclosureSEC source: 0000950170-24-133311 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,681 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $19.46 to $19.58, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 22:00 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 689 | $18.26 | $12,580.66 |
DisclosureSEC source: 0000950170-24-131590 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,136 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. F2 · price: The shares were sold in multiple transactions at prices ranging from $18.12 to $18.50, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| October 26, 2024 Filed Oct 29, 2024 20:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,345 | $19.42 | $84,379.90 |
DisclosureSEC source: 0000950170-24-118286 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,825 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:21 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,594 | $21.96 | $35,005.83 |
DisclosureSEC source: 0000950170-24-104021 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,170 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $21.815 to $22.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 22:33 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 715 | $22.83 | $16,325.60 |
DisclosureSEC source: 0000950170-24-101989 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,764 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. F2 · price: The shares were sold in multiple transactions at prices ranging from $22.72 to $22.915, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 03, 2024 Filed Aug 6, 2024 20:10 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 6,719 | $25.06 | $168,378.14 |
DisclosureSEC source: 0000950170-24-091805 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,479 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:29 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,345 | $23.66 | $102,802.70 |
DisclosureSEC source: 0000950170-24-087896 · ownership.xml · nonDerivative · entry 1 Xie Jian · CIK 0001819718 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,198 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.